Applying Risk-Based Oversight to Ensure Real-World Data Integrity

Clinical trials have undergone a period of immense change. Use of real-world data (RWD) is increasing. Regulators are backing both risk-based approaches and the use of real-world evidence (RWE). Artificial intelligence (AI) allows us to unlock better insights than ever before.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Press Release

CluePoints Appoints Martin Magazzolo as Chief Commercial Officer

Wayne, PA – July 27, 2026 – CluePoints, provider of leading statistical and AI-driven software solutions,...

Press Release

CluePoints and Tufts CSDD Publish Peer-Reviewed Evidence Quantifying the Financial Value of RBQM

New research demonstrates RBQM-enabled trials achieve up to 23x ROI and 19% shorter phase durations, providing...

Blog

The Hidden Inspection Risk in Your Medical and Safety Review Workflow

You have just been told an inspection is coming. Your team’s first reaction is not to...